Search Results
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
TRAE leading to death reported.The most common TRAEs are white blood cell count decreased, nausea and anemia. The incidence of interstitial lung disease was only 1.2%, all were grade 1.The Principal Investigator of the HeriCare-Breast01 study, Binghe Xu, academician of the
More news about: Innovent Biologics
Feb 12, 2026, 17:00 ET PTC Therapeutics Provides Regulatory Update on Translarna™
(loss of ambulation) as early as 10 years old, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and 20s.About PTC Therapeutics, Inc.PTC
More news about: PTC Therapeutics, Inc.
Feb 12, 2026, 13:15 ET Magnolia Medical Welcomes Sarah Huber as Senior Vice President, Sales
a key role in driving revenue growth, cultivating customer relationships, and increasing adoption of advanced respiratory solutions for obstructive lung disease. Throughout her career, she has held senior sales leadership roles at leading medical technology organizations, including Boston Scientific,
More news about: Magnolia Medical Technologies
Feb 12, 2026, 09:00 ET Four Seasons Celebrates Continued Leadership in 2026 Forbes Travel Guide Awards
Al Maryah IslandThe 4 Four Seasons restaurants that hold a Five-Star Rating are:Lung King Heen at Four Seasons Hotel Hong KongCaprice at Four Seasons Hotel Hong KongZi Yat Heen at Four Seasons
More news about: Four Seasons Hotels and Resorts
Feb 12, 2026, 07:34 ET 99mTc-maraciclatide Granted FDA Fast Track Designation for the Visualization of Inflammation in Interstitial Lung Disease
99mTc-maraciclatide as a diagnostic SPECT-CT agent for the "visualization of inflammation in the lungs of patients with known and suspected interstitial lung disease (ILD)."
More news about: Serac Healthcare
Feb 12, 2026, 02:01 ET J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
preclinical findings with early clinical observations, the research outlines a potential new treatment approach for patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have limited options after Tagrisso failure.EGFR-mutant NSCLC is driven by aberrant activation of EGFR signaling, and while
More news about: J INTS BIO
Feb 12, 2026, 01:18 ET Zendure ra mắt dòng SolarFlow tiên tiến, đánh dấu bước tiến thành một hệ sinh thái năng lượng thông minh toàn diện
ZendureZendure là đơn vị tiên phong toàn cầu trong lĩnh vực Hệ thống Quản lý Năng lượng Gia đình (HEMS) dạng cắm có trụ sở tại các trung tâm công nghệ của Thung lũng Silicon, Hoa Kỳ, Khu vực Vịnh Lớn ở Trung Quốc, Nhật Bản và Đức. Sứ mệnh của Zendure là cung cấp năng lượng sạch đáng tin cậy và giá cả phải chăng cho
More news about: Zendure DE GmbH
Feb 11, 2026, 23:18 ET Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
in the global clinical development of AK3280.IPF is a progressive, irreversible, and ultimately fatal interstitial lung disease characterized by fibrotic remodeling of lung tissue that leads to respiratory failure. The median survival following diagnosis is approximately 2–5 years. Currently approved
More news about: Arkbio
Feb 11, 2026, 23:18 ET Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
in the global clinical development of AK3280.IPF is a progressive, irreversible, and ultimately fatal interstitial lung disease characterized by fibrotic remodeling of lung tissue that leads to respiratory failure. The median survival following diagnosis is approximately 2–5 years. Currently approved
More news about: Arkbio
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Non-small Cell Lung Cancer Clinical Trial Analysis Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies,
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 08:30 ET IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
Non-small Cell Lung Cancer MarketNon-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease,
More news about: DelveInsight Business Research LLP
Feb 10, 2026, 16:05 ET TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday,
More news about: TransMedics Group, Inc.
Feb 10, 2026, 12:03 ET Cultural wave of 'becoming Chinese' gains momentum
the fifth spot on the all-time global box office charts.Next came Labubu. The "ugly-cute" doll, created by Hong Kong-born illustrator Kasing Lung and propelled by the Chinese brand Pop Mart, became a global phenomenon. Its whimsical grin, brandished by celebrities from Blackpink star Lisa to David
More news about: China Daily
Feb 10, 2026, 10:50 ET Oncology/Cancer Drugs Market to Reach $335.2 Billion by 2033 Globally, at 7.2% CAGR: Allied Market Research
On the other side lung cancer is projected to exhibit the fastest market growth during the forecast period, owing to higher incidence, increase in geriatric population, changes in lifestyle of people, and rise in smoking of tobacco that includes passive smoking, which may lead to lung cancer.North
More news about: Allied Market Research
Feb 10, 2026, 09:15 ET HELPFUL GUIDELINES TO NAVIGATE A CANCER DIAGNOSIS
information can be overwhelming. At least 20 million people are diagnosed with cancer worldwide every year—two million in the U.S. alone—with breast, lung, prostate, and colorectal cancers accounting for around 50% of all new cancer cases. Experience the full interactive Multichannel News Release
More news about: National Comprehensive Cancer Network® (NCCN®)
Feb 10, 2026, 09:10 ET Qnovia's Inhaled Nicotine Replacement Therapy Delivers Positive Results in First Human Study
smokers."Qnovia's RespiRx™ platform represents a category-defining shift, engineered to deliver controlled, pharmaceutical-grade nicotine directly to the lung — without combustion, smoke, or carcinogens — while preserving the rapid onset and sensory cues that reinforce smoking behavior. By restoring pulmonary
More news about: Qnovia, Inc.
Feb 10, 2026, 09:00 ET DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
dosed at 220 mg/kg. Over a 21-day period, animals were monitored for body weight and survival, followed by comprehensive lung assessment. Fibrotic burden was evaluated through lung weight, collagen content, fibrosis-related gene expression, and histopathological scoring. In this bleomycin-induced
More news about: Devonian Health Group Inc.
Feb 10, 2026, 08:07 ET On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully
methodologies. As a case study, GPR84, a GPCR with key role in immune and inflammatory disease, is discussed. This includes research on its functions in colitis, lung injury, and atopic dermatitis, the discovery and optimization of novel structural ligands, and ongoing new drug development efforts targeting colitis
More news about: Sanyou Bio
Feb 10, 2026, 08:00 ET Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
advancing its clinical trials in lung cancer.About Acclaim-3Acclaim-3 is a Phase 1/2 clinical trial evaluating the combination of REQORSA and Genentech's Tecentriq® (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC) who are candidates
More news about: Genprex, Inc.
Feb 09, 2026, 20:00 ET Kiến tạo kỳ nghỉ đông độc đáo cùng Club Med: Du lịch thảnh thơi theo phong cách all-inclusive
Roi Soleil lại khơi gợi vẻ đẹp cổ điển của vùng Engadin qua những cung đường trượt tuyết băng đồng hay những chuyến xe ngựa lãng mạn dạo quanh thung lũng phủ tuyết trắng. Tại Pháp, nếu Club Med Alpe d'Huez bừng sáng rực rỡ với đặc quyền hơn 300 ngày nắng mỗi năm, thì Club Med Val d'Isère tiếp tục khẳng
More news about: Club Med
Feb 09, 2026, 16:30 ET IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Feb 09, 2026, 10:02 ET NYU Langone Perlmutter Cancer Center Names Leading Clinician-Researcher as New Chair of Radiation Oncology
department. He also served as an officer of the hospital medical staff, among other institutional leadership roles.Gomez's research centers on lung cancer and the role of radiation therapy in oligometastatic disease, with a portfolio spanning biomarker-integrated local ablative strategies, minimal
More news about: NYU Langone Health System
Feb 09, 2026, 08:00 ET TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption
More news about: TransMedics Group, Inc.
Feb 09, 2026, 08:00 ET Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.